Addition of S-1 to Endocrine Therapy Postoperatively Improves Survival in HR+, HER2- Breast Cancer

Article

Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer.

Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer, according to results from a phase III study presented at the San Antonio Breast Cancer Symposium, held December 10-14, in San Antonio, Texas.

S-1 is a combination drug containing tegafur¾which is a 5-fluorouracil prodrug that inhibits DNA synthesis and cell division¾gimeracil, and oteracil¾which promote tegafur activity and prevent gastrointestinal toxicity, respectively¾in a molar ratio of 1.0 to 0.4 to 1.0. It is orally administered twice daily for 14 consecutive days at a dose specifcied by base on body surface area and creatine clearance, Masakazu Toi, MD, PhD, explained, adding that the 3-week administration was repeated for 1 year. 

Previous studies suggested that by combining tegafur with endocrine therapy could improve anti-tumor efficacy. “We hypothesized that adjuvant treatment with standard endocrine therapy and S-1 could improve survival outcomes compared with endocrine therapy alone,” Toi, professor of breast surgery at Kyoto University Hospital, said during a press briefing held at the conference. 

Toi and colleagues evaluated the combination (n = 959), compared with standard endocrine therapy alone (n = 973), in 1,932 patients with HR-positive, HER2-negative breast cancer. 

IDFS served as the primary endpoint of the study. Secondary endpoints included overall survival (OS), distant disease-free survival (DFS), DFS, safety, and predictive value of biomarkers.

The median follow-up after treatment was 51 months. The estimated 5-year IDFS in the S-1 combination arm was 86.9%, compared with 81.6% in the endocrine therapy alone arm (HR, 0.63; 95% CI, 0.49-0.81; P < .001). In total, IDFS events occurred in 101 patients and 155 patients, respectively (HR, 0.63; 95%CI, 0.49-0.81; = .0003).

Of note, the trial was terminated early because the primary endpoint was met at the interim analysis. 

Grade ≥ 3 associated with S-1 included decreased neutrophil (7.5%), diarrhea (1.9%), increase ALT (0.6%), fatigue (0.6%), decreased platelet count (0.5%), nausea (0.2%), and increased AST (0.1%).

“The oral formulation S-1, 1 year adjuvant therapy combined with endocrine therapy, would be an important treatment option for ER-positive and HER2-primary breast cancer patients having intermediate/high risk of recurrence,” Toi concluded. “Overall, the safety profile of S-1 was manageable.”

Reference:

 

Toi M, Imoto S, Ishida T, et al. Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial). Presented at: the San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract GS1-09.

Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content